Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Variation at Extra-epitopic Amino Acid Residues Influences Suppression of Influenza Virus Replication by M158-66 Epitope-Specific CD8+ T Lymphocytes.

van de Sandt CE, Pronk MR, van Baalen CA, Fouchier RAM, Rimmelzwaan GF.

J Virol. 2018 May 14;92(11). pii: e00232-18. doi: 10.1128/JVI.00232-18. Print 2018 Jun 1.

2.

The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.

Tilmanis D, van Baalen C, Oh DY, Rossignol JF, Hurt AC.

Antiviral Res. 2017 Nov;147:142-148. doi: 10.1016/j.antiviral.2017.10.002. Epub 2017 Oct 3.

3.

ViroSpot microneutralization assay for antigenic characterization of human influenza viruses.

van Baalen CA, Jeeninga RE, Penders GH, van Gent B, van Beek R, Koopmans MP, Rimmelzwaan GF.

Vaccine. 2017 Jan 3;35(1):46-52. doi: 10.1016/j.vaccine.2016.11.060. Epub 2016 Nov 26.

4.

Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts.

Stittelaar KJ, de Waal L, van Amerongen G, Veldhuis Kroeze EJ, Fraaij PL, van Baalen CA, van Kampen JJ, van der Vries E, Osterhaus AD, de Swart RL.

Viruses. 2016 Jun 14;8(6). pii: E168. doi: 10.3390/v8060168.

5.

Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture.

van Baalen CA, Els C, Sprong L, van Beek R, van der Vries E, Osterhaus AD, Rimmelzwaan GF.

J Clin Microbiol. 2014 May;52(5):1672-7. doi: 10.1128/JCM.03575-13. Epub 2014 Mar 12.

6.

The influenza virus: disease, diagnostics, and treatment.

Schutten M, van Baalen C, Zoeteweij P, Fraaij P.

MLO Med Lab Obs. 2013 Nov;45(11):38-40. Review. No abstract available.

PMID:
24313126
7.

HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption.

de Goede AL, van Deutekom HW, Vrancken B, Schutten M, Allard SD, van Baalen CA, Osterhaus AD, Thielemans K, Aerts JL, Keşmir C, Lemey P, Gruters RA.

AIDS. 2013 Nov 13;27(17):2679-89. doi: 10.1097/01.aids.0000433813.67662.92.

PMID:
24149085
8.

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.

Allard SD, De Keersmaecker B, de Goede AL, Verschuren EJ, Koetsveld J, Reedijk ML, Wylock C, De Bel AV, Vandeloo J, Pistoor F, Heirman C, Beyer WE, Eilers PH, Corthals J, Padmos I, Thielemans K, Osterhaus AD, Lacor P, van der Ende ME, Aerts JL, van Baalen CA, Gruters RA.

Clin Immunol. 2012 Mar;142(3):252-68. doi: 10.1016/j.clim.2011.10.010. Epub 2011 Nov 16.

PMID:
22177848
9.

Characterization of the human CD8⁺ T cell response following infection with 2009 pandemic influenza H1N1 virus.

Hillaire ML, van Trierum SE, Bodewes R, van Baalen CA, van Binnendijk RS, Koopmans MP, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2011 Nov;85(22):12057-61. doi: 10.1128/JVI.05204-11. Epub 2011 Sep 14.

10.

Annual vaccination against influenza virus hampers development of virus-specific CD8⁺ T cell immunity in children.

Bodewes R, Fraaij PL, Geelhoed-Mieras MM, van Baalen CA, Tiddens HA, van Rossum AM, van der Klis FR, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2011 Nov;85(22):11995-2000. doi: 10.1128/JVI.05213-11. Epub 2011 Aug 31.

11.

A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.

Bodewes R, Kreijtz JH, van Amerongen G, Geelhoed-Mieras MM, Verburgh RJ, Heldens JG, Bedwell J, van den Brand JM, Kuiken T, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2010 Aug;84(16):7943-52. doi: 10.1128/JVI.00549-10. Epub 2010 Jun 2.

12.

FATT-CTL assay for detection of antigen-specific cell-mediated cytotoxicity.

van Baalen CA, Gruters RA, Berkhoff EG, Osterhaus AD, Rimmelzwaan GF.

Cytometry A. 2008 Nov;73(11):1058-65. doi: 10.1002/cyto.a.20613.

13.

Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef.

Allard SD, Pletinckx K, Breckpot K, Heirman C, Bonehill A, Michiels A, van Baalen CA, Gruters RA, Osterhaus AD, Lacor P, Thielemans K, Aerts JL.

Vaccine. 2008 Jul 4;26(29-30):3735-41. doi: 10.1016/j.vaccine.2008.04.077. Epub 2008 May 20.

PMID:
18539368
14.

Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus.

Kreijtz JH, de Mutsert G, van Baalen CA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

J Virol. 2008 Jun;82(11):5161-6. doi: 10.1128/JVI.02694-07. Epub 2008 Mar 19.

15.

The loss of immunodominant epitopes affects interferon-gamma production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte response in vitro.

Berkhoff EG, Geelhoed-Mieras MM, Verschuren EJ, van Baalen CA, Gruters RA, Fouchier RA, Osterhaus AD, Rimmelzwaan GF.

Clin Exp Immunol. 2007 May;148(2):296-306. Epub 2007 Feb 26.

16.

Fluorescent antigen-transfected target cell cytotoxic T lymphocyte assay for ex vivo detection of antigen-specific cell-mediated cytotoxicity.

van Baalen CA, Kwa D, Verschuren EJ, Reedijk ML, Boon AC, de Mutsert G, Rimmelzwaan GF, Osterhaus AD, Gruters RA.

J Infect Dis. 2005 Oct 1;192(7):1183-90. Epub 2005 Aug 30.

PMID:
16136460
17.

The choice of antigen for therapeutic immunization against AIDS.

van Baalen CA, Stittelaar KJ, Osterhaus AD, Guillon C, Gruters RA.

Trends Immunol. 2002 Oct;23(10):478-9.

PMID:
12297418
18.

Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.

van Baalen CA, Guillon C, van Baalen M, Verschuren EJ, Boers PH, Osterhaus AD, Gruters RA.

Eur J Immunol. 2002 Sep;32(9):2644-52.

19.

Comparison of the efficacy of early versus late viral proteins in vaccination against SIV.

Stittelaar KJ, Gruters RA, Schutten M, van Baalen CA, van Amerongen G, Cranage M, Liljeström P, Sutter G, Osterhaus AD.

Vaccine. 2002 Jul 26;20(23-24):2921-7.

PMID:
12126903
20.

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.

Gruters RA, van Baalen CA, Osterhaus AD.

Vaccine. 2002 May 6;20(15):2011-5. Review.

PMID:
11983265
21.

Construction and characterisation of infectious recombinant HIV-1 clones containing CTL epitopes from structural proteins in Nef.

Guillon C, van Baalen CA, Boers PH, Verschuren EJ, Gruters RA, Osterhaus AD.

J Virol Methods. 2002 Jan;99(1-2):115-21.

PMID:
11684309
22.

Macrophage tropism of human immunodeficiency virus type 1 facilitates in vivo escape from cytotoxic T-lymphocyte pressure.

Schutten M, van Baalen CA, Guillon C, Huisman RC, Boers PH, Sintnicolaas K, Gruters RA, Osterhaus AD.

J Virol. 2001 Mar;75(6):2706-9.

23.

Decline of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in the peripheral blood of long-term nonprogressing macaques infected with SIVmac32H-J5.

Geretti AM, Hulskotte EG, Dings ME, van Baalen CA, van Amerongen G, Norley SG, Boers P, Gruters R, Osterhaus AD.

J Infect Dis. 1999 Oct;180(4):1133-41.

PMID:
10479140
24.

Vaccination with Rev and Tat against AIDS.

Osterhaus AD, van Baalen CA, Gruters RA, Schutten M, Siebelink CH, Hulskotte EG, Tijhaar EJ, Randall RE, van Amerongen G, Fleuchaus A, Erfle V, Sutter G.

Vaccine. 1999 Jun 4;17(20-21):2713-4. No abstract available.

PMID:
10418922
25.
27.

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus AD.

J Gen Virol. 1997 Aug;78 ( Pt 8):1913-8.

PMID:
9266987
28.

CD8+ cytotoxic T lymphocytes of a cynomolgus macaque infected with simian immunodeficiency virus (SIV) mac32H-J5 recognize a nine amino acid epitope in SIV Gag p26.

Geretti AM, Hulskotte EG, Dings ME, van Baalen CA, van Amerongen G, Osterhaus AD.

J Gen Virol. 1997 Apr;78 ( Pt 4):821-4.

PMID:
9129654
29.

Fine-specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1.

van Baalen CA, Klein MR, Huisman RC, Dings ME, Kerkhof Garde SR, Geretti AM, Gruters R, van Els CA, Miedema F, Osterhaus AD.

J Gen Virol. 1996 Aug;77 ( Pt 8):1659-65.

PMID:
8760412
30.

Human immunodeficiency virus type 1 (HIV-1)--and Epstein-Barr virus--specific cytotoxic T lymphocyte precursors exhibit different kinetics in HIV-1--infected persons.

Geretti AM, Dings ME, van Els CA, van Baalen CA, Wijnholds FJ, Borleffs JC, Osterhaus AD.

J Infect Dis. 1996 Jul;174(1):34-45.

PMID:
8656011
31.

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics.

Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, Eeftinck-Schattenkerk JK, Osterhaus AD, Schuitemaker H, Miedema F.

J Exp Med. 1995 Apr 1;181(4):1365-72.

32.

Kinetics and specificities of the T helper-cell response to gp120 in the asymptomatic stage of HIV-1 infection.

Geretti AM, Van Baalen CA, Borleffs JC, Van Els CA, Osterhaus AD.

Scand J Immunol. 1994 Apr;39(4):355-62.

PMID:
7908456
33.

Selective in vitro expansion of HLA class I-restricted HIV-1 Gag-specific CD8+ T cells: cytotoxic T-lymphocyte epitopes and precursor frequencies.

van Baalen CA, Klein MR, Geretti AM, Keet RI, Miedema F, van Els CA, Osterhaus AD.

AIDS. 1993 Jun;7(6):781-6.

PMID:
7689847
34.

Preservation of phenotype and function of positively selected virus-specific CD8+ T lymphocytes following anti-Fab detachment from immunomagnetic beads.

Geretti AM, Van Els CA, Van Baalen CA, Poelen MC, Osterhaus AD.

J Immunol Methods. 1993 May 5;161(1):129-33. No abstract available.

PMID:
8486924
35.
36.

Evidence for an NIH shift in oxidation of naphthalene by the marine cyanobacterium Oscillatoria sp. strain JCM.

Narro ML, Cerniglia CE, Van Baalen C, Gibson DT.

Appl Environ Microbiol. 1992 Apr;58(4):1360-3.

37.

Metabolism of phenanthrene by the marine cyanobacterium Agmenellum quadruplicatum PR-6.

Narro ML, Cerniglia CE, Van Baalen C, Gibson DT.

Appl Environ Microbiol. 1992 Apr;58(4):1351-9.

38.
39.
40.
41.

DL-7-azatryptophan and citrulline metabolism in the cyanobacterium Anabaena sp. strain 1F.

Chen CH, Van Baalen C, Tabita FR.

J Bacteriol. 1987 Mar;169(3):1114-9.

42.

Photosynthetic and respiratory rates of two psychrophilic diatoms.

Van Baalen C.

Plant Physiol. 1985 Aug;78(4):799-802.

43.

H2, N2, and O2 metabolism by isolated heterocysts from Anabaena sp. strain CA.

Smith RL, Kumar D, Zhang XK, Tabita FR, Van Baalen C.

J Bacteriol. 1985 May;162(2):565-70.

44.

Aerobic hydrogen production by the heterocystous cyanobacteria Anabaena spp. strains CA and 1F.

Zhang XK, Haskell JB, Tabita FR, Van Baalen C.

J Bacteriol. 1983 Dec;156(3):1118-22.

45.
46.

Biotransformation and toxicity of aniline and aniline derivatives of cyanobacteria.

Cerniglia CE, Freeman JP, Van Baalen C.

Arch Microbiol. 1981 Dec;130(4):272-5.

PMID:
6800332
47.

Novel mutant of Anabaena sp. strain CA which growns on N2 but not on combined nitrogen.

Gotto JW, Tabita FR, Van Baalen C.

J Bacteriol. 1980 Sep;143(3):1395-402.

48.

Heterocyst differentiation and tryptophan metabolism in the chanobacterium Anabaena sp. CA.

Bottomley PJ, Van Baalen C, Tabita FR.

Arch Biochem Biophys. 1980 Aug;203(1):204-13. No abstract available.

PMID:
6773477
49.

Oxidation of biphenyl by the cyanobacterium, Oscillatoria sp., strain JCM.

Cerniglia CE, Van Baalen C, Gibson DT.

Arch Microbiol. 1980 Apr;125(3):203-7.

PMID:
6769418
50.

Synthesis of nitrogenase and heterocysts by Anabaena sp. CA in the presence of high levels of ammonia.

Bottomley PJ, Grillo JF, Van Baalen C, Tabita FR.

J Bacteriol. 1979 Dec;140(3):938-43.

Supplemental Content

Loading ...
Support Center